Activating Innate Immunity in Triple-Negative Breast Cancer and Other Tumors
Steven J. O’Day, M.D., Executive Director of the Saint John’s Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research, was interviewed by the Journal of the National Comprehensive Cancer Network® (NCCN®), a peer-reviewed, indexed medical journal that provides the latest information about best clinical practices, health services research, and translational medicine.
Dr. O’Day’s was interviewed about his data from the open-label phase II IMPRIME 1 clinical trial presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract CT073). In this interview Dr. O’Day discusses the rationale for using Imprime PGG (a novel innate immune activator) to trigger immunity and possibly enhance response to pembrolizumab in patients with metastatic triple-negative breast cancer. He also explores the treatment’s potential in other tumor types.